glp 1 agonist parkinson Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease Emerging Frontiers in GLP-1 Therapeutics:

Clinical trials have demonstrated varying efficacy across the class, with weight reductions ranging from approximately 5-8% with liraglutide 3 mg to 15% with semaglutide 2.4 mg and 10-22% with tirzepatide, depending on dose

d-Allulose contributes no calories but substantial sweetness equivalent to glucose and 70% of sucrose 14,15 , yielding a zero-calorie sweetener

At the same time, concerns persist regarding the gastrointestinal side-effects commonly associated with GLP-1RAs, which may limit their applicability in patients with coexisting IBD

Preclinical studies have shown that GLP-1 RAs reduce oxidative stress, enhance neuronal survival, and improve synaptic plasticity in animal models of diabetes

June 11, 2019